Summary
In vitro and animal experiments have demonstrated the potential efficacy of using the bystander effect alone in the treatment of brain tumors. A known problem in some in vitro and in vivo experiments is that a fraction of cells engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene survive ganciclovir (GCV) treatment and undergo cell division. To prevent the recurrent growth of HSV-tk+ cells in the presence of GCV we examined the potential use of lethal or sublethal irradiation of Walker 256 carcinosarcoma cells selected for expression of the HSV-tk gene (Walker-tk+). Western blot analysis of Walter-tk+ cells showed similar levels of HSV-tk protein expression at 0, 1, 3, 6 and 9 days after lethal gamma-irradiation. In vitro, there was no difference in the bystander effect exerted by non-irradiated, sublethally irradiated or lethally irradiated Walker-tk+ cells on wild-type Walker cells in the presence of GCV. In vivo experiments demonstrated long-term survival (100 days) in rats implanted intrathecally with sublethally or lethally irradiated Walker-tk+ cells with GCV treatments. Intrathecal implantation of irradiated Walker-tk+ cells either pre-mixed with Walker cells or used in in situ treatment of established Walker tumors resulted in prolonged animal survival compared to controls (p < 0.05). These experiments suggest that the bystander tumoricidal effect is preserved despite gamma-irradiation of the HSV-tk modified tumor cells and that irradiation could be an effective method to prevent long-term resistance to GCV in HSV-tk+ tumor cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J, Klatzmann D: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90: 7024–7028, 1993
Culver K, Ram Z, Wallbridge S, Hiroyuki I, Oldfield E, Blaese R: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550–1552, 1992
Freeman S, Abboud C, Whartenby K, Packman C, Koeplin D, Moolten F, Abraham G: The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274–5283, 1993
Moolten F: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for prospective cancer control strategy. Cancer Res 46: 5276–5281, 1986
Oldfield E, Ram Z, Culver K, Blaese R, DeVroom H, Anderson W: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous gancielovir. Hum Gene Ther 4: 39–69, 1993
Ram Z, Culver K, Walbridge S, Blease R, Oldfield E: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53: 83–88, 1993
Takamiya Y, Short M, Moolten F, Fleet C, Mineta T, Breakfield X, Martuza R: An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 79: 104–110, 1993
Vrionis F, Wu J, Qi P, Cano W, Cherington V: Tumor cells expressing the herpes simplex virus thymidine kinase gene in the treatment of Walker 256 meningeal neoplasia in rats. J Neurosurg 84: 250–257, 1996
Vrionis F, Wu J, Qi P, Cano W Cherington V: Tumor cells expressing the herpes simplex virus thymidine kinase gene elicit a more potent bystander cytocidal effect than fibroblast virus producer cells in vitro. J Neurosurg 83: 698–704, 1995
Wu J, Cano W, Meylaerts S, Qi P, Vrionis F, Cherington V: Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35: 1094–1103, 1994
Golumbek P, Hamzeh F, Jaffee E, Levitsky H, Lietman P, Pardoll D: Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 12: 224–230, 1992
Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54: 5258–5261, 1994
Kooistra KL, Rodriguez M, Powis G, Yaksh TL, Harty GJ, Hilton JF, Laws ER: Development of experimental models for meningeal neoplasia using intrathecal injection of 9L gliosarcoma and Walker 256 carcinosarcoma in the rat. Cancer Res 46: 317–323, 1986
Cepko C: Retroviral infection of cells in vitro and in vivo. In: Ausubel F, Brent R, Kingston R, Moore D, Seidman J, Smith J, Struhl K (eds) Current protocols in molecular biology. Greene publishing associates, New York, 1992, pp 9.14.1–9.14.3
Hall E: Cell-Survival Curves. In: Hall E (ed) Radiobiology for the Radiologist. J.B. Lippincott, Philadelphia, 1988, pp 17–39
16.Albright N: Computer program for the analysis of cellular survival data. Radiation Res 112: 331–340, 1987
Liu Q-Y, Summers W: Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine Kinase: effects on catalytic activity. Virology 163: 638–642, 1988
Martuza R, Malick A, Markert J, Ruffner K,Coen D: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854–856, 1991
Boviatsis E, Park J, Sena-Esteves M, Kramm C, Chase M, Efird J, Wei M, Breakefield X, Chiocca E: Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54: 5745–5751, 1994
Ram Z, Walbridge S, Oshiro E, Viola J, Chiang Y, Mueller S, Blaese R, Oldfield E: Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 54: 2141–2145, 1994
Giangaspero F, Burger P: Correlations between cytologic composition and biologic behavior in the glioblastoma multiform. A postmortem study of 50 cases. Cancer 52: 2320–2333, 1983
Bi W, Parysek L, Warnick R, Stambrook P: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 4: 725–731, 1993
Barba D, Hardin J, Sadelain M, Gage F: Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91: 4348–4352, 1994
Tapscott S, Miller A, Olson J, Berger M, Groudine M, Spence A: Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994
Gansbacher B, Zier K, Cronin K, Hantzopoulos P, Bouchard B, Houghton A, Gilboa E, Golde D: Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood 80: 2817–2825, 1992
Gastl G, Finstad C, Guarini A, Bosl G, Gilboa E, Bander N, Gansbacher B: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52: 6229–6236, 1992
Al-Nabulsi I, Takamiya Y, Voloshin Y, Dritschilo A, Martuza R, Jorgensen T: Expression of thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Cancer Res 54: 5614–5617, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vrionis, F.D., Wu, J.K., Qi, P. et al. Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells. J Neuro-Oncol 30, 225–236 (1996). https://doi.org/10.1007/BF00177273
Issue Date:
DOI: https://doi.org/10.1007/BF00177273